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RESUMO – A síndrome de CANDLE, chronic atypical neutrophilic dermatosis with lipodystrophy and elevated temperature, é 
uma doença auto-inflamatória crónica, fisiopatologicamente condicionada pela disfunção intracelular do proteasoma/imuno-
proteasoma. 
Esta revisão descreve o reconhecimento da síndrome de CANDLE, os desenvolvimentos na compreensão do seu mecanismo 
patológico, os antecedentes genéticos e as estratégias terapêuticas emergentes para esta condição.   
PALAVRAS-CHAVE – Complexo de Endopeptidases do Proteassoma/genética; Doenças Hereditárias Autoinflamatórias; Doen-
ças da Pele/genética; Lipodistrofia; Síndrome.
Insights into CANDLE Syndrome 
ABSTRACT – Chronic atypical neutrophilic dermatosis with lipodystrophy and elevated temperature (CANDLE) syndrome is a re-
cently described chronic autoinflammatory disease, pathophysiologically related to intracellular proteasome/immunoproteasome 
dysfunction. This review chronicles the recognition of CANDLE syndrome, the developments in the understanding of the pathome-
chanism, genetic background, and the emerging therapeutic strategies of this condition.  
KEYWORDS – Hereditary Autoinflammatory Diseases; Lipodystrophy; Proteasome Endopeptidase Complex/genetics; Skin Disea-
ses/genetics; Syndrome.
INTRODUCTION
In 2010, António Torrelo and colleagues published a 
paper, thoroughly describing four patients with an early 
onset of recurrent fevers, annular violaceous skin lesions 
composed of infiltrates of atypical mononuclear cells and 
mature neutrophils, lipodystrophy and multisystemic inflam-
matory manifestations. These distinct clinical features led to 
an acronym for CANDLE syndrome (chronic atypical neutro-
philic dermatosis with lipodystrophy and elevated tempera-
ture).1 Subsequent studies provided evidence for the genetic 
nature of the syndrome, identifying a mutation in the genes 
encoding for a human immunoproteasome, and included 
this condition into a group of proteasome associated autoin-
flammatory syndromes (PRAAS).2 
To this date, 20 patients with CANDLE syndrome have 
been described in the literature. Apparently, the syndrome is 
not restricted to any ethnic group, with reported cases from 
Caucasian, Jewish, Spanish and Hispanic population.
Apart from CANDLE syndrome, PRAAS include three 
more entities: Japanese autoinflammatory syndrome with 
lipodystrophy (JASL); Nakajo-Nishimura syndrome (NNS); 
Joint contractures, muscular atrophy, microcytic anemia, 
panniculitis-associated lipodystrophy (JMP) syndrome. All 
these syndromes share similar clinical features and genetic 
background, most probably representing one disease spec-
trum.3 
In the current review, we discuss the clinical and labora-
tory features of the published cases of CANDLE syndrome, 
the latest clinical research in its pathophysiology and the pro-
mising new treatment strategies. 
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GENETIC BACKGROUND AND PATHOPHYSIOLOGY
With the recognition of CANDLE syndrome, abnormal 
inflammatory response was postulated, later attributed to 
proteasome–immunoproteasome dysfunction.1,2 The first 
identified mutations linked to CANDLE syndrome were limi-
ted to proteasome subunit β type 8 gene (PSMB8), which en-
codes the inducible β5i subunit of the proteasome. Most of 
patients reported, presented with homozygous or compound 
heterozygous mutation in PSMB8. However, one patient did 
not show a mutation in PSMB8 gene, suggesting that other 
genes may be involved in the aetiology of CANDLE syndro-
me.2 More recently, Brehm A et al, analysed eight patients 
with a clinical phenotype of CANDLE syndrome and recog-
nized 8 different mutations in further 4 genes that encode 
other proteasome subunits: proteasome subunit alpha-type 3 
(PSMB3); proteasome subunit beta-type 4 (PSMB4); proteaso-
me subunit beta-type 9 (PSMB9); and proteasome maturation 
protein (POMP).4 Proteasome gene mutation variably affects 
transcription, protein expression, protein folding, proteaso-
me assembly and proteasome activity.4 These findings fur-
ther confirmed considerable genetic heterogeneity underlying 
CANDLE syndrome, with recessive inheritance pattern in one 
proteasome subunit (monogenic, homozygous or compound 
heterozygous) or two different subunits digenic, or, rarely, in 
an autosomal dominant fashion.4,5
Proteasomes are large protease complexes located in cyto-
plasm, endoplasmic reticulum and nucleus, consisting of two 
components: the 19S regulatory particle and the 20S core 
particle. The eukaryotic proteasome degrades the majority of 
damaged or waste proteins in the cell under normal condi-
tions. Most substrates designated to degradation are first fla-
gged by ubiquitin conjugation system, which then directs them 
to the proteasome. 
Immunoproteasomes are special isoform of proteasomes, 
induced in most cells by oxidative stress and proinflammatory 
cytokines, mainly by type I interferons (IFNs). The type I IFNs 
bind to IFN-a membrane receptors, triggering a signal in the 
JAK/STAT pathway. Immunoproteasome complexes serve as 
processors of antigen for presentation by major histocompa-
tibility complex molecules and are involved in degradation of 
oxidised proteins in order to maintain cellular homeostasis. 
When the cell is exposed to certain triggers, such as viral in-
fection, the production of IFNs increases, leading to increased 
immunoproteasome formation and pathogen-derived protein 
degradation.6,7
In cells with a dysfunctional proteasome-immunoprotea-
some the catalytic activity is insufficient leading to intracellular 
accumulation of damaged proteins, particularly during cellu-
lar stress. These unprocessed proteins are further marked with 
more ubiquitin, increasing interferon signalling that leads to 
elevated production of proteasomes incapable of protein de-
gradation, creating a vicious cycle of inflammation.5,7
As a result, in CANDLE syndrome, proteasome defects 
lead to a continuous state of inflammation with exacerbations 
under situations of stress, when higher requirements of remo-
ving waste proteins are not met.5
CLINICAL PRESENTATION
CANDLE syndrome is an auto-inflammatory multisys-
tem disease. The first symptoms begin in early childhood 
(often in the first weeks of life) with skin eruptions and re-
current episodes of fever, which may occur daily, even with 
no apparent trigger. 
The most prominent skin manifestations, invariably pre-
sent in all patients, are annular erythematous or violaceous 
plaques with an elevated border and a flat centre (Fig. 1), 
lasting for a few days or weeks and progressing to a resi-
dual purpuric macule. Whereas they are almost always pre-
sent during childhood, they may be less conspicuous after 
puberty.2,5 Additionally, during early infancy CANDLE pa-
tients present with periocular erythematous and/or perioral 
edema and pernio-like lesions on acral sites, which also 
tend to fade with increasing age.1,2,5 
Lipodystrophy, a key manifestation of all PRAAS present 
in all published cases, starts in early childhood and has a 
progressive course. The loss of subcutaneous fat tissue is first 
noted on the face, with flattening or indentation of convex 
contours of the face, with subsequent involvement of trunk and 
upper limbs. The cause is not yet fully understood, but it has 
been suggested that downregulation of PSMB8 with increased 
IFN signalling, together with chronic inflammation may play 
a role in its pathogenesis.5,8 Swollen eyelids with periorbital 
erythema together with facial lipodystrophy confer typical phe-
notype of CANDLE syndrome patients (Fig. 2). 
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Figure 1 - Erythemato-violaceous plaques on the thighs in a patient 
with CANDLE syndrome (author's archive).
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The abdominal fat tissue, on the contrary, tends to be 
increased, which leads to metabolic disturbances, such as 
acanthosis nigricans and hirsutism. Hepatosplenomegaly, 
described in about 65% of CANDLE syndrome patients, fur-
ther contributes to a protuberant abdomen.2,5,9
Some degree of arthralgia has been described in 80% 
cases. Patients experience pain that predominantly affects 
small joints of the hands and feet. Interestingly, most pa-
tients complain of joint pain without overt signs of arthritis. 
With disease progression patients develop joint contractu-
res, which can lead to patients’ limited mobility when asso-
ciated with myositis and muscle wasting (Fig. 3).1,2,5,10
Other typical features observed in two thirds of pu-
blished cases include delayed physical development with 
growth retardation and failure to thrive. However, most pa-
tients with CANDLE do not show intellectual disability.5
With increasing number of published cases, several 
other clinical features were reported that may be variably 
linked to CANDLE syndrome: aseptic lymphocytic menin-
gitis (15%), basal ganglia calcifications (20%), diabetes 
mellitus, ear and nose chondritis, otitis, episcleritis, con-
junctivitis, lymphadenopathy, parotiditis, carditis, pneumo-
nitis, nephritis, epididymitis.1,2,5,9-16 
As shown, virtually every organ may be affected with on-
going and longstanding inflammation. The clinical and labo-
ratory features of published cases are summarized in Table 1. 
The course of the disease is variable, including some 
cases with fatal outcome.2,16
LABORATORY AND HISTOPATHOLOGIC FINDINGS
Abnormal laboratory values reflect the continuous 
chronic inflammation in patients with CANDLE syndro-
me. All affected individuals present with hypochromic 
anaemia and persistent elevation of acute phase reac-
tants. In addition, elevation of liver transaminases and 
hypertriglyceridemia are present in 65% and 45% of 
cases, respectively. Transient thrombocytosis or throm-
bocytopenia, neutropenia, lymphopenia can be variably 
observed. Autoimmunity markers are usually negative, 
although antinuclear antibodies titres may be increased 
in some patients.1,2,5
Skin biopsy is an essential diagnostic tool as the his-
tological features of cutaneous lesions in CANDLE syn-
drome are very characteristic and may permit an early 
diagnosis. The histological hallmark of skin lesions is 
the presence of atypical or immature myeloid cells that 
may mimic leukaemia cutis. This infiltrate localized at 
the perivascular and interstitial dermis extends into the 
subcutis and is further composed of mononuclear cells, 
neutrophils and eosinophils and some mature lympho-
cytes.19 Immunohistochemistry stains show strong posi-
tivity for myeloperoxidase and chloroacetate esterase, 
confirming presence of myeloid cells, and positivity for 
CD68 and CD163 indicating the presence of histiocytes 
and macrophages (Fig. 4). Additionally, CD123 positi-
ve staining shows admixture of plasmacytoid dendritic 
cells.19,20 
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Figure 2 - Facial lipodystrophy, erythematous periorbital plaques, and 
parotid gland enlargement (author's archive).
Figure 3 - Joint contractures and muscle atrophy on the hands 
(author's archive).
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Table 1 - Demographics, clinical and genetic features of the patients with CANDLE syndrome published in the 
literature
8y, 
M1,2
10y, 
F1,2
14y, 
F1,2
2y, 
F1,2
12,5y, 
M10
5,5y
M2
3,5y, 
M2
6y, 
F2
2,5y, 
F1,2
22y, 
M2
5M, 
F16
24y
M15
12y, 
F17
3y, 
M12
36y, 
F18
15y, 
F13
2y, 
M13
11y
F15
5y
M14
6y
M9
Mutation PSMB8 PSMB8 NA PSMB8 PSMB8
No 
PSMB8,
PSMB9,
PSMB10
PSMB8 PSMB8 PSMB8 SMB8 PSMB8
No 
PSMB8
Not 
tested
PSMB8 PSMB8
No 
PSMB8
PSMB8
No 
PSMB8
PSMB8 PSMB8
Age of presen-
tation
1M 6M
During 
first 
6M
1W 1M 2W 2M 2W 1M Infancy 5M 4M Infancy 11M 3M 3M 9D 4M
After 
birth
After 
birth
Fever + + + + + + + + + + + + + + + + + + + +
Annular 
plaques
+ + + + + + + + + + + + + + + + + + + +
Eyelid viola-
ceous swelling
+ + + + + + + + + + ND + ND + + + + + + +
Perioral swell-
ing
+ + ND ND + ND ND ND + + ND ND ND ND ND ND ND ND ND ND
Ear and nose 
chondritis
+ + ND ND + ND ND ND +/- ND ND ND + ND ND ND ND ND ND ND
Low weight 
and height
+ + + + + + ND ND ND + ND + ND + + + ND ND + +
Lipodystrophy + + + + + + + + + + + + + + + + + + + +
Alopecia 
areata
ND ND ND ND + ND ND ND ND ND ND ND ND ND ND ND ND ND ND ND
Prominent 
abdomen
+ +/- + + + + ND ND + ND ND + ND + + ND ND ND + +
Hirsutism/Hy-
pertrichosis
ND ND + + + ND + + ND + ND ND ND ND ND ND ND ND ND +
Lymphade-
nopathy
+ + ND + ND + + + + ND ND + + ND ND + ND ND + ND
Hepatomegaly + + + + + + + ND ND ND ND + + + ND + ND ND + +
Splenomegaly + ND + ND ND + + ND ND ND ND + + + ND + ND ND + ND
Arthralgia/joint 
contracture
+ + + + + + + + + + + + + ND + + ND + ND ND
Conjunctivi-
tis/nodular 
episcleritis
+ + ND + ND ND ND ND + ND ND ND ND ND ND ND ND ND ND ND
Epididymitis + ND ND ND ND ND + ND ND ND ND ND ND ND ND ND ND ND ND ND
Aseptic men-
ingitis
+ ND + ND ND ND ND ND ND ND ND ND ND ND ND ND ND + ND ND
Parotitis ND ND + + ND ND ND ND ND ND ND ND ND ND + ND ND ND ND ND
Intersititial 
lung disease
ND ND + ND ND ND ND ND ND ND ND ND ND ND ND ND ND ND ND ND
Nephritis ND ND + ND ND ND ND ND ND ND ND ND ND ND ND ND ND ND ND ND
Otitis ND ND + + + + ND ND ND ND ND ND ND ND ND ND ND ND ND
Increased 
erythrocyte 
sedimenta-
tion rate and 
C-reactive 
protein
+ + + + + + + + + + + + + + + + + + + +
Anemia + + + + + + + + + + + + + + + + + + +
Increased 
platelet count
+ ND ND + ND ND ND ND ND ND ND ND + + ND ND ND + ND ND
Elevated 
alanine ami-
notransferase 
and aspartate 
aminotrans-
ferase
+ + + + + + + ND + ND ND + + + ND ND + ND + ND
Increased 
triglyceride 
levels
ND ND + + ND + ND + ND ND ND + + + + ND ND ND + ND
Basal ganglia 
calcifications
+ ND + ND ND ND ND ND ND ND + ND + ND ND ND ND ND ND ND
PSMB – Proteasome subunit beta type-8; ND – negative or not determined
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DIFFERENTIAL DIAGNOSIS
Many of the clinical features seen in CANDLE syndrome 
resemble other inflammatory syndromes, such as chronic 
infantile, neurological, cutaneous and articular (CINCA) 
syndrome, cryopyrin-associated periodic syndromes (CAPS) 
in particular neonatal-onset multisystem inflammatory di-
sease (NOMID) and other type 1 interferonopathies.21,22
An important histologic differential diagnosis includes 
lymphoproliferation with cutaneous involvement as in acute 
myeloid leukaemia.19
TREATMENT
Patients with CANDLE syndrome respond partially to 
high doses of steroids, with reduction of febrile episodes, 
cutaneous lesions and arthralgia as well as partial or com-
plete normalization of laboratory values. With tapering, 
however, rebound occurs.2 Methotrexate can provide some 
improvement and can be considered the first line therapy.5 
Corticoid-sparing agents, such as azathioprine and 
cyclosporine, together with non-steroidal anti-inflammatory 
drugs (NSAIDs), colchicine and dapsone, have not shown 
consistent efficacy. Some patients experienced temporary im-
provement with TNF-alfa inhibitors, in others exacerbation 
was triggered.2,5
In addition, lipodystrophy has progressed in all patients 
despite immunosuppressive and cytokine targeted therapy.2
The identification of type I INF as the key-molecule in CAN-
DLE syndrome, permits introduction of new and more specific 
therapies. Accordingly, it has been proposed that blockage 
of IFN receptor signalling through inhibition of the Janus ki-
nases, JAK1/JAK2, may decrease interferon production and 
allow corticosteroid dose reduction. Baricitinib, a JAK inhibitor, 
has showed promising results and there is an ongoing trial for 
CANDLE (ClinicalTrials.gov: NCT01724580).23-25 
CONCLUSION
Recent recognition of CANDLE syndrome followed by 
intense study of published cases, allowed to gain new insi-
ghts into the genetics and the pathogenesis of this syndrome. 
However, the clinical course and range of organ involvement 
vary significantly between patients and the genotype-pheno-
type associations of CANDLE syndrome remain unknown. 
Recognizing the cutaneous features with characteristic his-
tological findings may aid for prompt diagnosis and early 
treatment that is key for the quality of life and survival of the 
affected patients. Baricitinib represents a new promising the-
rapy along with other targeted interventional strategies that 
may arise with the aim of facilitating clinical management. 
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Figure 4 - Histological findings include perivascular and interstitial infiltrate composed of atypical myeloid cells, eosinophils, neutrophils and mature 
lymphocytes, with positive myeloperoxidase and CD68 staining. 
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1.  Which of these clinical features is the most 
consistent with CANDLE syndrome?
a) Cognitive impairment
b) Progressive sensorineural hearing loss
c) Obesity
d) Ophthalmologic changes 
e) Progressive loss of peripheral fat 
2. Which of the following statement is/are true 
about CANDLE syndrome?
a) Histological examination reveals dense eosino-
philic infiltrate in perivascular and interstitial lo-
calization
b) The predominant cells that comprise the infiltrate 
in the dermis are mature neutrophils
c) Hypochromic anemia is present virtually in all pa-
tients
d) Markers of autoimmunity are frequently positive
e) Brain imaging studies may show basal ganglia 
calcification
 
3. Which of the following syndromes is not asso-
ciated with proteasome dysfunction? 
a) CANDLE (Chronic Atypical Neutrophilic Derma-
tosis with Lipodystrophy and Elevated temperatu-
re) syndrome
b) Chronic Infantile, Neurological, Cutaneous and 
Articular (CINCA) syndrome
c) Nakajo-Nishimura syndrome (NNS)
d) Japanese autoinflammatory syndrome with lipo-
dystrophy (JASL)
e) Joint contractures, muscular atrophy, microcytic 
anemia, panniculitis-associated lipodystrophy (JMP) 
syndrome
 
4. Type 1 IFN is the key molecule in CANDLE 
syndrome. Which of the following intracellu-
lar signalling pathway is triggered by type I 
IFNs?  
a) JAK/STAT
b) RAS/MAPK
c) IL-1β pathway
d) IL-17 pathway
tESt YourSElF
Key: 1e; 2ce; 3b; 4a.
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